
What We're Reading: FDA Will Require Strong Warnings on Opioid Labels
What we're reading, September 1, 2016: new, stronger warnings on opioid labels; why competition hasn't curbed drug price hikes; and Zika funding bill likely won't pass the Senate.
The FDA will require strong warnings on opioids and certain anxiety medications.
Why do drug prices continue to rise despite competition in the market? Since the United States allows drug manufacturers to set their own prices—unlike most other developed nations—prices for medicines continue to be higher than other countries in the world simply because companies can raise their prices,
The Zika fund may be close to running out, but there isn’t much hope that Congress will pass a bill requesting funding to fight the virus. The problem is that the Senate’s bill to provide $1.1 billion in Zika funding includes a rider that blocks funding for Planned Parenthood,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.















































